Comorbidity and competing risks for mortality in men with prostate cancer

Cancer

Volumn 117, Issue 20, 2011, Pages 4642-4650

  Daskivich, Timothy J ^a   Chamie, Karim ^a   Kwan, Lorna ^a   Labo, Jessica ^a   Dash, Atreya ^b   Greenfield, Sheldon ^b,c   Litwin, Mark S ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

comorbidity; outcome assessment; prostate; prostatic neoplasms

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; PROSTATE SPECIFIC ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CAUCASIAN; CEREBROVASCULAR DISEASE; CHARLSON COMORBIDITY INDEX SCORE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DEMENTIA; DIABETES MELLITUS; FOLLOW UP; GLEASON SCORE; HEART INFARCTION; HEMIPLEGIA; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; KIDNEY DISEASE; LEUKEMIA; LIFE EXPECTANCY; LIVER DISEASE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; METASTASIS; MORTALITY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEGRO; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PEPTIC ULCER; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; UNITED STATES; WATCHFUL WAITING;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; COMORBIDITY; DATA INTERPRETATION, STATISTICAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FOLLOW-UP STUDIES; HEALTH STATUS; HISPANIC AMERICANS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 80053920100     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26104     Document Type: Article

References (28)

1. Bill-Axelson AHL, Ruutu M, Haggman M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005; 352: 1977-1984. (Pubitemid 40638368)
2. Gore JL, Kwan L, Lee SP, Reiter RE, Litwin MS,. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer. J Natl Cancer Inst. 2009; 101: 888-892.
3. Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA. 2000; 283: 354-360. (Pubitemid 30051753)
4. Wei JT, Dunn RL, Sandler HM, et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol. 2002; 20: 557-566. (Pubitemid 34072540)
5. Talcott JA, Manola J, Clark JA, et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol. 2003; 21: 3979-3986. (Pubitemid 46606212)
6. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007; 177: 2106-2131. (Pubitemid 46726449)
7. Mohler J, Bahnson RR, Boston B, et al. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. J Natl Compr Canc Netw. 2010; 8: 162-200.
8. Walz J, Suardi N, Shariat SF, et al. Accuracy of life tables in predicting overall survival in patients after radical prostatectomy. BJU Int. 2008; 102: 33-38. (Pubitemid 351799455)
9. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987; 40: 373-383. (Pubitemid 17055592)
10. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J,. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol. 1996; 156: 127-132. (Pubitemid 26185654)
11. Fowler JE Jr, Terrell FL, Renfroe DL,. Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy. J Urol. 1996; 156: 1714-1718. (Pubitemid 26344025)
12. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J,. Long-term survival among men with conservatively treated localized prostate cancer. JAMA. 1995; 274: 626-631.
13. Cowen ME, Halasyamani LK, Kattan MW,. Predicting life expectancy in men with clinically localized prostate cancer. J Urol. 2006; 175: 99-103. (Pubitemid 41797102)
14. Tewari AJC, Divine G, Crawford ED, Gamito EJ, Demers R, Menon M,. Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol. 2004; 171: 1513-1519. (Pubitemid 38365408)
15. Walz J, Gallina A, Saad F, et al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol. 2007; 25: 3576-3581. (Pubitemid 47372594)
16. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM,. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol. 2003; 56: 221-229. (Pubitemid 36513483)
17. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280: 969-974. (Pubitemid 28445094)
18. Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Blute ML,. Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. J Urol. 2008; 179: 1354-1360; discussion 60-61.
19. Fine JP, Gray RJ,. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94: 496-509.
20. Kim HT,. Cumulative incidence in competing risk data and competing risks regression analysis. Clin Cancer Res. 2007; 13: 559-565. (Pubitemid 46225362)
21. Satagopan J, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD,. A note on competing risks in survival data analysis. Br J Cancer. 2004; 91: 1229-1235. (Pubitemid 39424779)
22. Albertsen PC, Hanley JA, Gleason DF, Barry MJ,. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998; 280: 975-980. (Pubitemid 28445095)
23. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009; 302: 1202-1209.
24. Litwin MS, Greenfield S, Elkin EP, Lubeck DP, Broering JM, Kaplan SH,. Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice. Cancer. 2007; 109: 1777-1783. (Pubitemid 46668540)
25. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H,. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol. 2000; 164: 101-105. (Pubitemid 30434268)
26. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005; 294: 433-439. (Pubitemid 41124175)
27. Oefelein MG, Agarwal PK, Resnick MI,. Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era. J Urol. 2004; 171: 1525-1528. (Pubitemid 38365410)
28. Smaletz O, Scher HI, Small EJ, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 2002; 20: 3972-3982.